Management Following Fracture

| PQRI Data Collection Sheet | | | | | |
|--|--------------------------------------|-----|----|--|-----------------|
| | | | | / / | ☐ Male ☐ Female |
| Patient's Name Pra | Practice Medical Record Number (MRN) | | | Birth Date (mm/dd/yyyy) | Gender |
| National Provider Identifier (NPI) | | | | Date of Service | |
| Clinical Information | | | | Billing Information | |
| Step 1 Is patient eligible for this measure? | | | | | |
| | | Yes | No | Code Required on Claim Form | |
| Patient is aged 50 years and older on date of encounter. | | | | Verify date of birth on claim form. | |
| Patient has a line item diagnosis of fracture of the hip, spine or distal radius AND a CPT E/M Service Code for this visit OR there is a CPT Procedure Code. | | | | Refer to coding specifications document for list of applicable codes. Codes determining a patient's eligibility must be reported on the same claim as | |
| If No is checked for any of the above, STOP. Do not report a CPT category II code. | | | | the quality code(s) identified below. | |
| Step 2 Does patient meet or have an acceptable reason for not meeting the measure? | | | | | |
| Central Dual-Energy X-ray Absorptiometry (DXA) Measurement OR Pharmacologic Therapy¹ | | Yes | No | Code to be Reported on Line 24D of Paper Claim Form, if <i>Yes</i> (or Service Line 24 of Electronic Claim Form) | |
| DXA ordered | | | | 3096F | |
| DXA performed | | | | 3095F | |
| Pharmacologic therapy prescribed ² | | | | 4005F | |
| Not ordered, performed or prescrib of the following reasons: | ed for one | | | | |
| Medical (eg, not indicated, contraindicated, other medical reason) | | | | 3096F-1P OR 3095F-1P OR 4005-1P | |
| Patient (eg, patient declined, ecc social, religious, other patient rea | | | | 3096F-2P OR 3095F-2P OR | 4005F–2P |
| System (eg, resources to perform the services not available, other reason attributable to health care delivery system) | | | | 3096F-3P OR 3095F-3P OR 4005F-3P | |
| Document reason here and in medical chart. | | | | If No is checked for all of the above, report 3096F–8P OR 3095F–8P OR 4005F–8P (Central DXA measurement was not ordered or performed and a pharmacologic therapy for osteoporosis was not prescribed, reason not otherwise specified.) | |

Note: This measure should be reported at one of the following two instances if management following fracture has occurred or is planned within 3 months of fracture.

- 1) During an office visit with ICD-9-CM diagnosis code for fracture of hip, spine or distal radius OR
- 2) At the time of a procedure to repair a fracture

Prior DXA status or already on pharmacologic therapy pre-fracture meets this measure



Management Following Fracture

continued from previous page

¹Pharmacologic Therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modules or SERMs (raloxifene).

²"Prescribed" includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.